Navigation Links
Trubion Pharmaceuticals to Present at the Lazard Capital Markets Healthcare Investor Conference
Date:11/21/2007

SEATTLE, Nov. 21 /PRNewswire-FirstCall/ -- Trubion Pharmaceuticals Inc. (Nasdaq: TRBN) today announced that Dr. Peter Thompson, president, chief executive officer and chairman of Trubion, is scheduled to present a corporate update at the upcoming Lazard Capital Markets Healthcare Investor Conference to be held at The New York Palace Hotel. Dr. Thompson is scheduled to present Nov. 27, 2007, at 2:30 p.m. Interested parties may access the live audio webcast of the presentation by visiting the Wall Street Webcasting link at http://www.wsw.com/webcast/lz4/trbn.

About Trubion

Trubion is a biopharmaceutical company creating a pipeline of product candidates to treat autoimmune disease and cancer. The company's product candidates are novel proteins known as single-chain polypeptides and are designed using its SMIP(TM) custom drug assembly technology. In less than 24 months, the company designed, developed and submitted to the FDA an Investigational New Drug (IND) application for its lead product candidate, TRU-015, which has completed a Phase IIb clinical trial for the treatment of rheumatoid arthritis. In December 2005, the company entered into a collaboration agreement with Wyeth for the development and worldwide commercialization of certain therapeutics, including TRU-015. In addition, Trubion's TRU-016 program targets CD37, an antigen present on B cells, for the treatment of non-Hodgkin's lymphoma and chronic lymphocytic leukemia. The company filed an IND for TRU-016 in the fourth quarter of 2007. Trubion currently retains all development and commercialization rights for the TRU-016 program. For additional information, visit

SOURCE Trubion Pharmaceuticals Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Trubion Pharmaceuticals to Present at Upcoming Investor Conferences
2. Trubion Pharmaceuticals Announces Upcoming Presentations at American College of Rheumatology Annual Scientific Meeting
3. Trubion Pharmaceuticals Inc. Reports Third Quarter and Nine Months 2007 Financial Results
4. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
5. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
6. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
7. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
8. Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results
9. Nabi Biopharmaceuticals to Present at Upcoming Industry Conferences
10. Anadys Pharmaceuticals Appoints Steve Worland, Ph.D. as President and Chief Executive Officer
11. Poniard Pharmaceuticals Announces Participation in Upcoming Conferences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/16/2015)...  In recognition of World Hemophilia Day, Biogen  (NASDAQ: ... illuminate more than 15 prominent landmarks red throughout ... Zakim Bridge and Prudential Tower, Chicago,s ... Superdome and Denver,s Coors Field ... 17, and coincide with hemophilia community events in a dozen ...
(Date:4/16/2015)... , April 16, 2015 ... the Russian pharmaceutical investment and R&D group, ... collaboration for research, development and commercialization of ... with the intention to stimulate the ...      (Logo: http://photos.prnewswire.com/prnh/20150416/739742-a) ,     (Logo: ...
(Date:4/16/2015)... 2015 Avelas Biosciences, an in vivo ... announced today that it has initiated a Phase 1b ... women with primary, non-recurrent breast cancer undergoing surgery. In ... addition of Steven Chen , M.D., as vice ... dose escalation study will enroll up to 39 women ...
(Date:4/16/2015)... April 16, 2015 Fairleigh Dickinson ... V. Gulfo to become the Executive Director of ... FDU announced the kick-off of the Initiative for ... by Dr. Gulfo, under the Rothman Institute of ... Business) and in collaboration with FDU’s School of ...
Breaking Biology Technology:Biogen Shines A Light On Hemophilia Community By Illuminating U.S. Landmarks Red On World Hemophlia Day 2Biogen Shines A Light On Hemophilia Community By Illuminating U.S. Landmarks Red On World Hemophlia Day 3Biogen Shines A Light On Hemophilia Community By Illuminating U.S. Landmarks Red On World Hemophlia Day 4Lancet and ChemRar High Tech Center Have Announced a Partnership in the Development and Production of Novel Drugs in Russia 2Avelas Biosciences Initiates Phase 1b Trial of AVB-620 in Breast Cancer Patients 2Avelas Biosciences Initiates Phase 1b Trial of AVB-620 in Breast Cancer Patients 3Dr. Joseph V. Gulfo Named Executive Director of Fairleigh Dickinson University’s Rothman Institute to Spearhead New Initiative for Patient-Centered Innovation (iPCI) 2Dr. Joseph V. Gulfo Named Executive Director of Fairleigh Dickinson University’s Rothman Institute to Spearhead New Initiative for Patient-Centered Innovation (iPCI) 3
... MADISON HEIGHTS, Mich., Nov. 5 InfuSystem,Holdings, Inc. (OTC ... ambulatory infusion pumps and associated clinical services,today announced ... the,third quarter ended September 30, 2008., Mr. ... pleased,to report a solid 14.5% increase in revenue ...
... http://www.amdl.com ),AMDL, Inc. (Amex: ADL ), announced today ... has retired at the close of business,October 31, 2008. ... leadership,team and a director for many years. The Company ... About AMDL:, Headquartered in Tustin, CA with ...
... from Same Prior Year Period, DUBLIN, Calif., Nov. ... company dedicated to the discovery and,development of novel cancer ... nine months ended September 30, 2008., Total revenues ... $6.1 million for the same prior year period. Total ...
Cached Biology Technology:InfuSystem Holdings Reports 14.5% Revenue Increase and Approximately $3.6 Million of Adjusted EBITDA for the Third Quarter of 2008 2InfuSystem Holdings Reports 14.5% Revenue Increase and Approximately $3.6 Million of Adjusted EBITDA for the Third Quarter of 2008 3InfuSystem Holdings Reports 14.5% Revenue Increase and Approximately $3.6 Million of Adjusted EBITDA for the Third Quarter of 2008 4InfuSystem Holdings Reports 14.5% Revenue Increase and Approximately $3.6 Million of Adjusted EBITDA for the Third Quarter of 2008 5InfuSystem Holdings Reports 14.5% Revenue Increase and Approximately $3.6 Million of Adjusted EBITDA for the Third Quarter of 2008 6InfuSystem Holdings Reports 14.5% Revenue Increase and Approximately $3.6 Million of Adjusted EBITDA for the Third Quarter of 2008 7InfuSystem Holdings Reports 14.5% Revenue Increase and Approximately $3.6 Million of Adjusted EBITDA for the Third Quarter of 2008 8InfuSystem Holdings Reports 14.5% Revenue Increase and Approximately $3.6 Million of Adjusted EBITDA for the Third Quarter of 2008 9InfuSystem Holdings Reports 14.5% Revenue Increase and Approximately $3.6 Million of Adjusted EBITDA for the Third Quarter of 2008 10InfuSystem Holdings Reports 14.5% Revenue Increase and Approximately $3.6 Million of Adjusted EBITDA for the Third Quarter of 2008 11AMDL, Inc.'s President & CEO Mr. Gary Dreher Retires 2SuperGen Reports 2008 Third Quarter Financial Results 2SuperGen Reports 2008 Third Quarter Financial Results 3SuperGen Reports 2008 Third Quarter Financial Results 4SuperGen Reports 2008 Third Quarter Financial Results 5SuperGen Reports 2008 Third Quarter Financial Results 6SuperGen Reports 2008 Third Quarter Financial Results 7SuperGen Reports 2008 Third Quarter Financial Results 8SuperGen Reports 2008 Third Quarter Financial Results 9SuperGen Reports 2008 Third Quarter Financial Results 10
(Date:3/23/2015)... , March 23, 2015   HOYOS Labs ... management company, today announced that the Company will demonstrate ... both enterprise and consumers at Connect:ID on March 23 ... HOYOS Labs will highlight the IEEE Biometric Open ... ; and enterprise access control system. BOPS was ...
(Date:3/20/2015)... 2015 Research and Markets ( ... "India Sensors Market Forecast and Opportunities 2020" ... sensor market is projected to grow at a ... electronics, automotive, industrial and healthcare sectors are the ... In addition, adoption of MEMS technology in sensors ...
(Date:3/20/2015)... Research and Markets ( http://www.researchandmarkets.com/research/vkzvcs/iris_biometrics ) has ... Strategic Business Report" report to their offering. ... US$ Thousands. The report provides separate comprehensive analytics for the ... , Europe , Asia-Pacific ... Latin America . Annual estimates and forecasts ...
Breaking Biology News(10 mins):HOYOS Labs to Showcase Host of Biometrics Technologies at Connect:ID in Washington, D.C. 2HOYOS Labs to Showcase Host of Biometrics Technologies at Connect:ID in Washington, D.C. 3India Sensors Market Forecast and Opportunities 2020 - STMicroelectronics held the largest share in 2014 2India Sensors Market Forecast and Opportunities 2020 - STMicroelectronics held the largest share in 2014 3Iris Biometrics - Global Strategic Business Report 2015: System & Network Access Control - A Robust Market Opportunity in the Offing 2Iris Biometrics - Global Strategic Business Report 2015: System & Network Access Control - A Robust Market Opportunity in the Offing 3Iris Biometrics - Global Strategic Business Report 2015: System & Network Access Control - A Robust Market Opportunity in the Offing 4Iris Biometrics - Global Strategic Business Report 2015: System & Network Access Control - A Robust Market Opportunity in the Offing 5
... solar cells are expected to be highly efficient, thinner, more ... cells of today. This could pave the way for them ... globally. Nanyang Technological University (NTU) today announced that it ... set up a new research centre that will pioneer the ...
... co-authored by Columbia Engineering professor Kartik Chandran and recently ... , shows that reducing nitrogen pollution generated by wastewater ... well as the expected benefits for the environment. ... U.S. who worked on the study, along with James ...
... BELLINZONA (Switzerland) July 28, 2011 A paper ... , describes a novel, proprietary monoclonal antibody (FI6) discovered ... for Research in Biomedicine ("IRB") and the UK Medical ... that targets all 16 hemagglutinin subtypes of influenza A ...
Cached Biology News:NTU unveils new center to develop solar cells and clean energy systems of tomorrow 2NTU unveils new center to develop solar cells and clean energy systems of tomorrow 3New study outlines economic and environmental benefits to reducing nitrogen pollution 2New study outlines economic and environmental benefits to reducing nitrogen pollution 3Humabs discovers the first antibody to neutralize both group 1 and group 2 influenza A viruses 2
Special grade: for electrophoresis...
... DAPI (4,6-diamidine-2-phenylindole, dihydrochloride) is ... the nucleus blue in color. ... excellent contrast to red fluorochromes ... Red, or R-Phycoerythrin. DAPI can ...
Contact us for more information...
... sensitive silver stain. Reproducible ... baths or reversers needed. ... polysaccharides. Linear protein-to-stain color ... multiple gels per tray. ...
Biology Products: